Teva Pharmaceutical Industries (NYSE:TEVA) has seen its stock move steadily over the past month, gaining about 5%. Investors are eyeing recent performance trends and looking for clues about where it ...

Jefferies London Healthcare Conference Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast of the presentation, visit Teva’s Investor Relations ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this ...

Harel Insurance Investments & Financial Services Ltd. increased its Teva holding to 6.84% of its reportable U.S. equity ...

A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?

Sound Shore Management, an investment management firm, has released its investor letter for the third quarter of 2023. A copy of the same can be downloaded here. In the third quarter, the Sound Shore ...

Explore how Teva Pharmaceutical (NYSE:TEVA) strengthens its global presence and influence in Healthcare Stocks worldwide.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

The last remaining defendants in New York’s once-sprawling opioid trial settled on Thursday. By Sarah Maslin Nir The agency cited Teva’s continuing supply problems as well as those of other drug ...

Teva Pharmaceutical Industries Ltd. will pay $35 million to settle claims it delayed generic competition in the asthma inhaler market.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday. A number of ...